BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17-21, 2025, in Los Angeles, California.As part of the meeting's educational programming, there will be a full day master course on Sunday, May 18, 2025, entitled: "Clinical Applications for Psychiatric Practice: Ketamine and TMS." The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approaches for improving patient outcomes through evidence-based, interventional psychiatry. It will feature several prominent clinician-researchers discussing innovative therapeutic approaches, including two presenters from BrainsWay, Dr. Richard Bermudes, the Company's Chief Medical Officer and Dr. Colleen Hanlon, BrainsWay's Vice President of Medical Affairs."The future of mental health care depends on accessible, effective treatments like TMS. I'm honored to contribute to this dialogue at the APA symposium," said Dr. Bermudes. "This year's APA Annual Meeting is an important opportunity to connect with practitioners who are reshaping psychiatric care."BrainsWay will also be hosting live demonstrations of its Deep Transcranial Magnetic Stimulation (Deep TMS ) system at its exhibit booth, offering a hands-on opportunity to interact with this innovative treatment modality. Deep TMS is FDA-cleared to treat Major Depressive Disorder (MDD), Anxious Depression, Late-Life Depression, Obsessive-Compulsive Disorder (OCD) and Smoking Addiction.About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its ...Full story available on Benzinga.com